| __timestamp | BioCryst Pharmaceuticals, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 79838000 |
| Thursday, January 1, 2015 | 1896000 | 121816000 |
| Friday, January 1, 2016 | 2699000 | 117633000 |
| Sunday, January 1, 2017 | 1702000 | 4577000 |
| Monday, January 1, 2018 | 471000 | 12670000 |
| Tuesday, January 1, 2019 | 4101000 | 12135000 |
| Wednesday, January 1, 2020 | 1676000 | 18942000 |
| Friday, January 1, 2021 | 7264000 | 32328000 |
| Saturday, January 1, 2022 | 6594000 | 44678000 |
| Sunday, January 1, 2023 | 4661000 | 65486000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for PTC Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, PTC Therapeutics has seen a significant increase in its cost of revenue, peaking at approximately $65 million in 2023, a staggering 700% rise from 2014. In contrast, BioCryst Pharmaceuticals experienced a more modest growth, with costs increasing from $122,000 in 2014 to around $4.7 million in 2023, marking a 38-fold increase. This divergence highlights the varying operational strategies and market conditions faced by these companies. As the biotech sector continues to evolve, monitoring these financial metrics provides valuable insights into company performance and industry trends.
Cost of Revenue: Key Insights for Johnson & Johnson and BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Sanofi vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and PTC Therapeutics, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Incyte Corporation and BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Viatris Inc. vs PTC Therapeutics, Inc.
Insmed Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs PTC Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
PTC Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: BioCryst Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.